Document:

EX-10.3

 Exhibit 10.3 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

SECOND AMENDMENT TO 

RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Second Amendment To Research Collaboration And License Agreement (“Second Amendment”), effective as of the date of last signature below
(the “Second Amendment Effective Date”), confirms the mutual understanding between Merck Sharp & Dohme Corp. (“Merck”) and Bionomics Limited (“Bionomics”). 

WHEREAS, Merck and Bionomics have entered into that certain Research Collaboration and License Agreement relating to α7 Activators, effective
June 23, 2014, as amended by the First Amendment effective October 2, 2015, (as amended, the “Agreement”); and 
 WHEREAS, the Parties
wish to amend the Agreement to extend the Research Program Term, revise the [***] as set forth in Schedule 1.1, update the Research Plan; and confirm the number of FTEs to be utilized by Bionomics in performing its responsibilities under the
Research Plan. 
 NOW, THEREFORE, the Parties hereby amend the Agreement as follows: 

 

	1.	 In accordance with Section 2.14.1 of the Agreement, the Research Program Term is hereby extended to
include an initial Extension Research Program Term of [***] , commencing on [***] and expiring on [***] (“First Extension Research Program Term”). 

 

	2.	 The Parties hereby replace in its entirety the first sentence of Section 2.8 with the following:

 “During the Research Program Term, Merck will provide Bionomics with research funding pursuant to Section 5.2
for FTEs at the FTE Rate as follows: [***] FTEs during the [***] Research [***] Program Term as set forth in the Research Plan, and [***] FTEs during [***]; provided, however, that the foregoing number of FTEs shall be subject to the Joint Research
Committee’s right to amend the Research Plan to (x) require additional FTEs or (y) reduce the number of FTEs, in which case of (x) and/or (y) as applicable, the following number of FTEs shall be so adjusted.” 

 

	3.	 Effective as of [***] shall be deleted in its entirety and replaced with Annex I attached hereto and made part
of this Second Amendment. 

  

	4.	 Schedule 1.79, “Research Plan,” shall be deleted in its entirety and replaced with Annex II attached
hereto and made part of this Second Amendment. 

  

	5.	 All other terms and conditions of the Agreement not specifically modified by this Second Amendment shall remain
in full force and effect. 

  

	6.	 Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the
Agreement. 

  

	7.	 On and after the Second Amendment Effective Date, each reference in the Agreement to this
“Agreement”, “hereunder”, “herein”, “hereof” or words of like import referring to the 

  
 1 

	 	Agreement shall mean and be a reference to the Agreement as amended by this Second Amendment. 

  

	8.	 This Second Amendment may be signed in any number of counterparts (facsimile and electronic transmission
included), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After facsimile or electronic transmission, the parties agree to execute and exchange documents with original signatures.

 IN WITNESS WHEREOF, the parties have caused this Second Amendment to the Agreement to be BIONOMICS LIMITED executed by their duly
authorized representatives. 
  

									
	MERCK SHARP & DOHME CORP.	 		 	BIONOMICS LIMITED
					
	By:	 	[***]	 		 	By:	 	/s/ Deborah Rathjen
	Name:	 	[***]	 		 	Name:	 	Deborah Rathjen
	Title:	 	[***]	 		 	Title:	 	CEO, Managing Director
					
	Date:	 	May 05, 2016	 		 	Date:	 	09/05/2016

  
 2 

 ANNEX I 

Schedule 1.1 

[***] 

  
 3 

 ANNEX II 

Schedule 1,79 

Research Plan 
 [***] 

  
 4EX-10.4

 Exhibit 10.4 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

THIRD AMENDMENT TO 

RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Third Amendment to Research Collaboration And License Agreement (“Third Amendment”), effective as of the date of last signature below
(the “Third Amendment Effective Date”), confirms the mutual understanding between Merck Sharp & Dohme Corp. (“Merck”) and Bionomics Limited (“Bionomics”). 

WHEREAS, Merck and Bionomics have entered into that certain Research Collaboration and License Agreement relating to α7 Activators, effective
June 23, 2014, as amended by the First Amendment effective October 2, 2015, and the Second Amendment effective June 23, 2016 (as amended, the “Agreement”); and WHEREAS, the Parties wish to amend the Agreement to
extend the Research Program Term and confirm the number of FTE’s to be utilized by Bionomics in performing its responsibilities under the Research Plan. 

NOW, THEREFORE, the Parties hereby amend the Agreement as follows: 
  

	1.	 In accordance with Section 2.14.1 of the Agreement, the Research Program Term is hereby extended to
include a second Extension Research Program Term of [***], commencing on [***] (“Second Extension Research Program Term”). 

  

	2.	 The Parties hereby replace in its entirety the first sentence of Section 2.8 with the following:

 “During the Research Program Term, Merck will provide Bionomics with research funding pursuant to Section 5.2
for FTEs at the FTE Rate as follows: [***] FTEs during the [***] Research [***] Program Term as set forth in the Research Plan, and [***] FTEs during [***]; provided, however, that the foregoing number of FTEs shall be subject to the Joint Research
Committee’s right to amend the Research Plan to (x) require additional FTEs or (y) reduce the number of FTEs, in which case of (x) and/or (y) as applicable, the following number of FTEs shall be so adjusted.” 

 

	3.	 All other terms and conditions of the Agreement not specifically modified by this Third Amendment shall remain
in full force and effect. 

  

	4.	 Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the
Agreement. 

  

	5.	 On and after the Third Amendment Effective Date, each reference in the Agreement to this “Agreement”,
“hereunder”, “herein”, “hereof’ or words of like import referring to the Agreement shall mean and be a reference to the Agreement as amended by this Third Amendment. 

 

	6.	 This Third Amendment may be signed in any number of counterparts (facsimile and electronic transmission
included), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After facsimile or electronic transmission, the parties agree to execute and exchange documents with original signatures.

  
 1 

 IN WITNESS WHEREOF, the parties have caused this Third Amendment to the Agreement to be executed by their
duly authorized representatives. 
  

									
	MERCK SHARP & DOHME CORP.	 		 	BIONOMICS LIMITED
					
	By:	 	[***]	 		 	By:	 	Deborah Rathjen
	Name:	 	[***]	 		 	Name:	 	Deborah Rathjen
	Title:	 	[***]	 		 	Title:	 	CEO & Managing Director
					
	Date:	 	November 8, 2016	 		 	Date:	 	November 4, 2016

  
 2EX-10.5

 Exhibit 10.5 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

FOURTH AMENDMENT TO 

RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Fourth Amendment To Research Collaboration And License Agreement (“Fourth Amendment”), effective as of the date of last signature below
(the “Fourth Amendment Effective Date”), confirms the mutual understanding between Merck Sharp & Dohme Corp. (“Merck”) and Bionomics Limited
(“Bionomics”). 
 WHEREAS, Merck and Bionomics have entered into that certain Research Collaboration and License Agreement relating to
α7 Activators, effective June 23, 2014, as amended by the First Amendment effective October 2, 2015, and the Second Amendment effective June 23, 2016 and the Third Amendment effective December 23, 2016 (as amended, the
“Agreement”); and 
 WHEREAS, the Parties wish to amend the Agreement to extend the Research Program Term and confirm the number of
FTE’s to be utilized by Bionomics in performing its responsibilities under the Research Plan. 
 NOW, THEREFORE, the Parties hereby amend the Agreement
as follows: 
  

	1.	 In accordance with Section 2.14.1 of the Agreement, the Research Program Term is hereby extended to
include a Third Extension Research Program Term of [***], commencing on [***] (“Third Extension Research Program Term”). 

  

	2.	 The Parties hereby replace in its entirety the first sentence of Section 2.8 with the following:

 “During the Research Program Term, Merck will provide Bionomics with research funding pursuant to Section 5.2
for FTEs at the FTE Rate as follows [***] FTEs during [***] Research [***] Program Term as set forth in the Research Plan, and [***] FTEs during [***]; provided, however, that the foregoing number of FTEs shall be subject to the Joint Research
Committee’s right to amend the Research Plan to (x) require additional FTEs or (y) reduce the number of FTEs, in which case of (x) and/or (y) as applicable, the following number of FTEs shall be so adjusted.” 

 

	3.	 All other terms and conditions of the Agreement not specifically modified by this Fourth Amendment shall remain
in full force and effect. 

  

	4.	 Capitalized terms used and not otherwise defined herein shall have the respective meanings set forth in the
Agreement. 

  

	5.	 On and after the Fourth Amendment Effective Date, each reference in the Agreement to this
“Agreement”, “hereunder”, “herein”, “hereof’ or words of like import referring to the Agreement shall mean and be a reference to the Agreement as amended by this Fourth Amendment. 

 

	6.	 This Fourth Amendment may be signed in any number of counterparts (facsimile and electronic transmission
included), each of which shall be deemed an original, but all of which shall constitute one and the same instrument. After facsimile or electronic transmission, the parties agree to execute and exchange documents with original signatures.

  
 1 

 IN WITNESS WHEREOF, the parties have caused this Fourth Amendment to the Agreement to be executed by their
duly authorized representatives. 
  

									
	MERCK SHARP & DOHME CORP.	 		 	BIONOMICS LIMITED
					
	By:	 	[***]	 		 	 By:
	 	/s/ Deborah Rathjen
	Name:	 	[***]	 		 	Name:	 	Deborah Rathjen
	Title:	 	[***]	 		 	Title:	 	CEO and Managing Director
					
	Date:	 	April 4, 2017	 		 	Date:	 	April 21, 2017

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00337-of-00352.parquet"}]]